



**For more information: David Murphy**  
Director of Marketing Communications  
CMS  
Tel: (314) 812-4320  
[dmurphy@cmsrtp.com](mailto:dmurphy@cmsrtp.com)  
9991-950-96a

**CMS and Sixel Technologies Preview Focal DVS at ASTRO**  
**New Plan Review Module to Support *In Vivo* Dose Verification System**

**St. Louis, MO** (October 16, 2005) – CMS, Inc., the leading provider of clinical software solutions to the radiotherapy market, is previewing Focal DVS, an innovative dose verification and plan review tool, at ASTRO in Denver, Colorado on October 16 – 19, 2005. This product prototype is the result of a development and co-marketing agreement between CMS and Sixel Technologies announced earlier this year and represents an important advance in the field of delivery QA and adaptive radiotherapy.

Focal DVS, a new software module within CMS's Focal product line, will integrate with Sixel's **DVS®**, Dose Verification System to collect information such as patient name, sensor identification and dose information from Sixel's implantable dosimeters and will display this information alongside other patient treatment and image data stored in the Focal system. This unique software application will allow physicians to obtain actual verification of dose at depth and compare measured dose at various points of interest with the expected dose from the treatment plan. With this data, physicians will have the ability to verify actual dose delivery and make real-time adjustments to treatment plans based on a comparison of measured and predicted dose. Sixel's implantable sensors are currently under FDA review and will be commercially available following 510(k) product clearance.

According to CMS President and CEO Andrew Cowen, "the advent of intensity modulated radiotherapy is transforming the delivery of radiotherapy and a growing number of clinics around the world are utilizing IMRT to develop highly conformal treatment plans that deliver increased dose to target volumes while sparing adjacent critical structures. While many facilities are implementing new image-guided treatment techniques to ensure that these more precise dose distributions are accurately placed inside the body, clinicians still lack critical data regarding actual dose distribution. The dose verification, QA and plan comparison tools being developed by CMS and Sixel will enable clinicians to safely and effectively realize the benefits of IMRT. These

-more-

applications will also provide valuable feedback for clinicians throughout the course of treatment that can be used to modify patient plans, providing a pathway to truly adaptive radiotherapy.”

CMS, Inc. is a world leader in the development and support of radiation treatment planning software. With more than 1,500 treatment planning systems installed worldwide, CMS is a global resource to radiation oncology departments for treatment planning software and prostate brachytherapy systems. A privately held corporation, CMS is headquartered in St. Louis, Missouri with regional offices in Freiburg, Germany; Tokyo, Japan; Shanghai, China; and Sydney, Australia.

Sicel Technologies Inc. is a privately owned company headquartered in Raleigh, North Carolina. The Company was established in 1999 to developing telemetric systems that use miniature implantable wireless sensor technologies to continuously provide real time feedback about biological and physiological changes in cell and organ systems. The Company's efforts have been focused in the oncology market segment to develop products that can continuously monitor changes within tumors of patients undergoing radiation and chemotherapy. DVS® is a Registered Trademark of Sicel Technologies